Photosensitive rash induced by nivolumab
An. bras. dermatol
;
97(5): 648-650, Sept.-Oct. 2022. graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1403151
ABSTRACT
Abstract The therapeutic approach to metastatic melanoma has revolutionized the clinical course of this disease. Since 2011, different immunotherapeutic drugs have been approved. Nivolumab is a humanized immunoglobulin IgG4 monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with his ligand PD-L1. The authors present a new case of photosensitivity induced by nivolumab. The photo exposed distribution of the eruption, the sun exposure prior to the beginning of the eruption, and the chronological relationship with the beginning of the treatment are data that have allowed us to confirm the suspected clinical diagnosis.
Full text:
Available
Index:
LILACS (Americas)
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2022
Type:
Article
Affiliation country:
Spain
Institution/Affiliation country:
Hospital Universitario San Cecilio/ES
Similar
MEDLINE
...
LILACS
LIS